OK, this one's easy. Ionis' partner, Biogen ( BIIB -0.38% ), won U.S. regulatory approval for Spinraza in treating spinal muscular atrophy just a few weeks ago. Additional filings have been made in Europe, Japan, Canada, and Australia. Spinraza should be a huge success for both companies.